NASDAQ:IKNA Ikena Oncology (IKNA) Stock Price, News & Analysis $1.70 +0.02 (+1.19%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$1.67▼$1.7350-Day Range$1.28▼$1.8252-Week Range$1.02▼$5.95Volume127,350 shsAverage Volume345,881 shsMarket Capitalization$82.04 millionP/E RatioN/ADividend YieldN/APrice Target$3.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Ikena Oncology alerts: Email Address Ikena Oncology MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside76.5% Upside$3.00 Price TargetShort InterestHealthy1.67% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.44Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.22) to ($1.02) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.45 out of 5 starsMedical Sector313th out of 936 stocksBiological Products, Except Diagnostic Industry43rd out of 154 stocks 3.3 Analyst's Opinion Consensus RatingIkena Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageIkena Oncology has only been the subject of 2 research reports in the past 90 days.Read more about Ikena Oncology's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.67% of the float of Ikena Oncology has been sold short.Short Interest Ratio / Days to CoverIkena Oncology has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Ikena Oncology has recently decreased by 70.17%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldIkena Oncology does not currently pay a dividend.Dividend GrowthIkena Oncology does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IKNA. Previous Next 3.0 News and Social Media Coverage News SentimentIkena Oncology has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Ikena Oncology this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for IKNA on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Ikena Oncology to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ikena Oncology insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.94% of the stock of Ikena Oncology is held by insiders.Percentage Held by Institutions75.00% of the stock of Ikena Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ikena Oncology's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Ikena Oncology are expected to grow in the coming year, from ($1.22) to ($1.02) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ikena Oncology is -1.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ikena Oncology is -1.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIkena Oncology has a P/B Ratio of 0.48. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Ikena Oncology's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIHow a $0.25 cent option contract makes my top traders feelIf you don’t know me, I’ve been in the markets for over 40 years… but recently, I’ve discovered a breakthrough that might be my favorite strategy of ALL time! While I kept the finer details of these $0.25 Cent Trades under wraps until recently…Click now to see for yourself what $0.25 Cent Trades is all about About Ikena Oncology Stock (NASDAQ:IKNA)Ikena Oncology, Inc. operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway. The company also develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.Read More IKNA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IKNA Stock News HeadlinesMay 29, 2024 | msn.comWedbush downgrades Ikena, cites discontinuation of lead assetMay 29, 2024 | msn.comIkena Oncology Discontinues IK-930 Program And Cuts Workforce, Analyst Calls It 'Disappointing'July 26, 2024 | DTI (Ad)We’re in a code red crisis and 99% of Americans are clueless Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES! May 29, 2024 | msn.comThis American Airlines Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For WednesdayMay 28, 2024 | marketwatch.comIkena Oncology to Cut Half of Workforce, Discontinue Development of CandidateMay 28, 2024 | msn.comIkena to cut workforce by 53%, explore strategic optionsMay 28, 2024 | globenewswire.comUPDATE – Ikena Oncology Announces Strategic UpdateMay 28, 2024 | globenewswire.comIkena Oncology Announces Strategic UpdateJuly 26, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.May 13, 2024 | investorplace.comIKNA Stock Earnings: Ikena Oncology Beats EPS for Q1 2024May 13, 2024 | globenewswire.comIkena Oncology Reports First Quarter 2024 Financial Results and Corporate UpdateApril 21, 2024 | finance.yahoo.comIkena Oncology, Inc. (IKNA)April 10, 2024 | globenewswire.comIkena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology ForumMarch 19, 2024 | markets.businessinsider.comThe Analyst Landscape: 4 Takes On Ikena OncologyMarch 14, 2024 | finance.yahoo.comIkena Oncology Full Year 2023 Earnings: EPS Beats Expectations, Revenues LagMarch 13, 2024 | markets.businessinsider.comIkena Oncology’s Promising Drug Pipeline Merits a Buy RatingMarch 12, 2024 | benzinga.comIkena Oncology: Q4 Earnings InsightsMarch 12, 2024 | finanznachrichten.deIkena Oncology, Inc.: Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial ResultsSee More Headlines Receive IKNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ikena Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IKNA CUSIPN/A CIK1835579 Webikenaoncology.com Phone857-273-8343FaxN/AEmployees70Year FoundedN/APrice Target and Rating Average Stock Price Target$3.00 High Stock Price Target$4.00 Low Stock Price Target$2.00 Potential Upside/Downside+75.4%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-68,170,000.00 Net MarginsN/A Pretax Margin-2,638.17% Return on Equity-42.38% Return on Assets-35.91% Debt Debt-to-Equity RatioN/A Current Ratio15.85 Quick Ratio15.85 Sales & Book Value Annual Sales$9.16 million Price / Sales9.01 Cash FlowN/A Price / Cash FlowN/A Book Value$3.52 per share Price / Book0.49Miscellaneous Outstanding Shares48,260,000Free Float45,391,000Market Cap$82.52 million OptionableNot Optionable Beta0.48 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Mark Manfredi Ph.D. (Age 53)President, CEO & Director Comp: $810.69kDr. Jotin Marango M.D. (Age 45)Ph.D., CFO & Head of Corporate Development Comp: $577.12kMr. Bob LallySenior Vice President of Finance & OperationsMs. Srividya Subramanian Esq.Ph.D., VP & Deputy General CounselMs. Samantha VuksanicHead of Human ResourcesMr. Jeffrey Ecsedy Ph.D. (Age 54)Chief Development Officer Mr. Navin Parwani M.S.VP & Head of QualityMr. David Damphousse M.S.Senior Vice President of Clinical Development OperationsDr. Caroline Germa M.D. (Age 52)Ph.D., Chief Medical Officer Mr. Valdas Jurkauskas Ph.D.Senior Vice President of Technical OperationsMore ExecutivesKey CompetitorsSpero TherapeuticsNASDAQ:SPROVor BiopharmaNYSE:VORXilio TherapeuticsNASDAQ:XLOInventivaNASDAQ:IVAG1 TherapeuticsNASDAQ:GTHXView All CompetitorsInstitutional OwnershipJacobs Levy Equity Management Inc.Bought 457,245 shares on 5/16/2024Ownership: 1.064%Acadian Asset Management LLCBought 261,060 shares on 5/10/2024Ownership: 0.586%Marquette Asset Management LLCBought 72,890 shares on 5/7/2024Ownership: 0.151%View All Institutional Transactions IKNA Stock Analysis - Frequently Asked Questions How have IKNA shares performed this year? Ikena Oncology's stock was trading at $1.97 on January 1st, 2024. Since then, IKNA stock has decreased by 13.7% and is now trading at $1.70. View the best growth stocks for 2024 here. How were Ikena Oncology's earnings last quarter? Ikena Oncology, Inc. (NASDAQ:IKNA) issued its quarterly earnings results on Monday, May, 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.40) by $0.12. When did Ikena Oncology IPO? Ikena Oncology (IKNA) raised $125 million in an IPO on Friday, March 26th 2021. The company issued 7,800,000 shares at $15.00-$17.00 per share. Jefferies, Cowen, Credit Suisse and William Blair served as the underwriters for the IPO. How do I buy shares of Ikena Oncology? Shares of IKNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IKNA) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ikena Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ikena Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
